ReShape Lifesciences Inc. Company Profile

Background

ReShape Lifesciences Inc. is a physician-led company specializing in weight loss and metabolic health solutions. The company's mission is to provide innovative, minimally invasive products and services that effectively manage and treat obesity and related metabolic diseases. ReShape Lifesciences is recognized for its significant contributions to the medical device industry, particularly in developing technologies that offer alternatives to traditional bariatric surgeries.

Key Strategic Focus

ReShape Lifesciences focuses on delivering a comprehensive portfolio of weight loss and metabolic health solutions. Their core objectives include:

• Lap-Band® System: An FDA-approved, minimally invasive device for long-term obesity treatment, serving as an alternative to more invasive surgical procedures.

• ReShape Diabetes Neuromodulation System: An investigational implant that utilizes bio-electronic neuromodulation of vagus nerve branches to regulate plasma glucose levels in Type 2 diabetes patients.

• Obalon® Gastric Balloon System: A non-surgical, swallowable, gas-filled intragastric balloon designed to facilitate weight loss.

The company targets the global obesity and metabolic disorder markets, emphasizing minimally invasive solutions that improve patient outcomes and quality of life.

Financials and Funding

As of July 23, 2025, ReShape Lifesciences Inc. (NASDAQ: RSLS) has a stock price of $3.02, reflecting a 4.47% increase from the previous close. In February 2025, the company completed an upsized public offering, raising approximately $6.0 million through the sale of 2,575,107 units at $2.33 per unit. Each unit comprised one common share and one warrant to purchase an additional common share. The proceeds are intended to support strategic initiatives, including the pending merger with Vyome Therapeutics and the asset sale to Biorad Medisys.

Pipeline Development

ReShape Lifesciences' product pipeline includes:

• ReShape Diabetes Neuromodulation System: Received a Notice of Allowance from the U.S. Patent and Trademark Office in March 2025 for a patent entitled "Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic Control System and Methods," providing protection until April 12, 2039.

• Lap-Band® 2.0 FLEX: An enhanced version of the Lap-Band® System, with distribution agreements in place, including a partnership with Liaison Medical for distribution in Canada.

Technological Platform and Innovation

ReShape Lifesciences differentiates itself through proprietary technologies and innovative methodologies:

• Proprietary Technologies: The company's portfolio includes the Lap-Band® System, ReShape Diabetes Neuromodulation System, and Obalon® Gastric Balloon System, each designed to offer minimally invasive solutions for weight loss and metabolic health.

• Scientific Methodologies: The ReShape Diabetes Neuromodulation System employs bio-electronic neuromodulation of vagus nerve branches to regulate plasma glucose levels, representing a novel approach to treating Type 2 diabetes.

Leadership Team

The leadership team at ReShape Lifesciences includes:

• Paul F. Hickey: President and Chief Executive Officer.

• Thomas Stankovich: Chief Financial Officer.

Both executives bring extensive experience in the medical device industry, guiding the company's strategic direction and operational execution.

Leadership Changes

In June 2025, ReShape Lifesciences announced a strategic headcount reduction, estimated to save over $750,000 annually, representing approximately 23% of wage expenses. This decision was part of a broader effort to operate more efficiently while preserving core capabilities.

Competitor Profile

Market Insights and Dynamics

The global obesity treatment market is highly competitive, with numerous companies offering surgical, pharmaceutical, and non-invasive solutions. The market is characterized by rapid technological advancements and a growing demand for effective weight loss treatments.

Competitor Analysis

Key competitors include:

• Allergan: Offers the ORBERA® Intragastric Balloon System, a non-surgical weight loss solution.

• Medtronic: Provides the EndoBarrier® Gastrointestinal Liner, an endoscopic device for weight loss and diabetes management.

• Johnson & Johnson: Through its subsidiary Ethicon, offers various bariatric surgical solutions.

These competitors focus on different aspects of weight loss treatment, from surgical procedures to non-invasive devices, contributing to a diverse and dynamic market landscape.

Strategic Collaborations and Partnerships

ReShape Lifesciences has engaged in significant collaborations to enhance its market position:

• Vyome Therapeutics: Entered into a definitive merger agreement in July 2024 to combine in an all-stock transaction, aiming to advance immuno-inflammatory assets and explore opportunities between the Indian and U.S. markets.

• Biorad Medisys: Simultaneously entered into an asset purchase agreement to sell substantially all of ReShape's assets, including the Lap-Band® System, Obalon® Gastric Balloon System, and the Diabetes Neuromodulation System, for $5.16 million in cash.

Operational Insights

ReShape Lifesciences has implemented strategic measures to strengthen its market position:

• Cost Reduction Initiatives: Announced a workforce reduction in June 2025, estimated to save over $750,000 annually, representing approximately 23% of wage expenses.

• Manufacturing Optimization: Completed the transition of Lap-Band® manufacturing to a U.S.-based facility in July 2021, aiming to reduce costs, improve margins, and gain direct control over the manufacturing process.

Strategic Opportunities and Future Directions

ReShape Lifesciences is poised to capitalize on several strategic opportunities:

• Merger with Vyome Therapeutics: The pending merger is expected to create a combined entity focused on immuno-inflammatory diseases, leveraging synergies between the U.S. and Indian markets.

• Asset Sale to Biorad Medisys: The sale of assets is anticipated to provide financial resources to support the company's strategic initiatives and streamline operations.

• Product Development: Continued focus on advancing the ReShape Diabetes Neuromodulation System and expanding the distribution of the Lap-Band® 2.0 FLEX, particularly in international markets.

Contact Information

• Website: www.reshapelifesciences.com

• Investor Relations: Investor Relations

• Social Media:

• LinkedIn: ReShape Lifesciences on LinkedIn

• Twitter: @ReShapeLifesci

• Facebook: ReShape Lifesciences on Facebook

ReShape Lifesciences continues to innovate in the field of weight loss and metabolic health, striving to provide effective and minimally invasive solutions for patients worldwide.